2nd Annual Pharma Pricing, Reimbursement and Market Access

$499.00

SKU: PHP13890 Category:

Description

Report Code: PHP13890. April 2013. Toronto.

Article 1

Common Drug Review – A 10th Anniversary Perspective: Trajectory to Date and Directions Ahead

Chander Sehgal
Director, Common Drug Review and Optimal Use of Drugs
CADTH

Article 2

Insights into Drug Shortages in Canada: What’s Happening?

Jeff Morrison
Director, Government Relations and Public Affairs
Canadian Pharmacists Association

Article 3

Development of Orphan Drug Regulations

Marcin Boruk
Senior Policy Analyst, Office of Legislative and Regulatory Modernization
Health Canada

Article 4

Quebec Report – INESSS, BAP+ 15 and More

France Mignault
Director, Government and Community Relations Janssen
RX&D Access Lead

Article 5

PMPRB – 25 Years On

W. Neil Palmer
President & Principal Consultant
PDCI Market Access Inc.

Article 6

Canadian Pricing in a Changing Environment

Claudia Neuber
Director of Pricing and Contracting
AstraZeneca Canada Inc.

Article 7

An Update on pCODR

Mona Sabharwal, BSCPhm, PharmD
Executive Director
pan-Canadian Oncology Drug Review

Article 8

PCODR / PERC Recommendations: What’s Unique and What Lessons Can We Learn?

Dr. Judith L. Glennie
President
J.L. Glennie Consulting Inc.

Article 9

Case Study of a Patient Group Submission to the Common Drug Review: Kuvan™ for PKU

John Adams
President & CEO
Canadian PKU and Allied Disorders Inc. (CanPKU)

Article 10

The Evolution of the pan-Canadian Pricing Alliance (pCPA)

Wayne Critchley
Senior Associate
Global Public Affairs

Article 11

Leading Developments in Cancer Patient Support

William Hryniuk, MD, FRCP(C)
Vice-President (Research)
CAREpath Inc.

Article 12

Aligning Strategy to Objectives and User Acceptance

Paula Allen
Vice President, Research and Integrative Solutions
Morneau Shepell

Article 13

The Ground is Moving for Private Plans – What’s Next?

Barbara Martinez
Benefits Solutions Practice Leader
Great-West Life

Article 14

Making Better Use of Private Sector Plan Data

Michael Sullivan, RPh, BSP, MBA
President
Cubic Health Inc.

Article 15

Engaging Pharmacists for Better Patient Care

Steve Long
National Director Public Policy
Shoppers Drug Mart

Article 16

Subsequent Entry Biologics – A Market Access Perspective

Arvind Mani, MA, MBA
Director, Market Access and Policy Research
PDCI Market Access Inc.

Article 17

Subsequent Entry Biologics – A Regulatory Perspective

Anne Tomalin
Strategic Regulatory Services
OptumInsight

Article 18

Current Issues in International Trade: A Pharma Perspective

Paul Moen
President
MoenGlobal Advisors Inc.

Article 19

Panel Discussion – Discounting and Rebates

Alan West
Partner, Life Sciences
Gowlings LLP